Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most prevalent cause of dementia, predominantly affecting aging populations. It is characterized by memory impairment, cognitive decline, and behavioral disturbances resulting from neuronal loss and synaptic dysfunction. Molecular hallmarks include extracellular amyloid-β (Aβ) plaque deposition, intracellular tau hyperphosphorylation, neuroinflammation, and oxidative stress, which collectively contribute to neural damage and cognitive impairment. Recent advances highlight the importance of early diagnosis through biomarkers such as cerebrospinal fluid Aβ/tau ratios, PET imaging, and emerging blood-based diagnostic tools. Current therapeutic strategies primarily provide symptomatic relief, yet novel disease-modifying approaches targeting Aβ, tau, neuroimmune pathways, and gene-based therapies are under active investigation. Future prospects emphasize personalized medicine, lifestyle-based prevention, and integration of multi-modal biomarkers to enhance early detection and treatment outcomes. This review summarizes updated insights into pathophysiology, diagnostic progress, and evolving therapeutic innovations in Alzheimer’s disease.